Anders Österborg

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: CELL HOST & MICROBE. 2024;32(2):156-161.e3

Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant

Muller TR; Gao Y; Wu J; Ribeiro O; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Soderdahl G; Smith CIE; Lore K; Chen MS; Ljungman P; Ingelman-Sundberg HM; Ljunggren H-G; Osterborg A; Sette A; Grifoni A; Aleman S; Buggert M
Article: SCIENCE IMMUNOLOGY. 2023;8(90):eadh0687

SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19

Cai C; Gao Y; Adamo S; Rivera-Ballesteros O; Hansson L; Osterborg A; Bergman P; Sandberg JK; Ljunggren H-G; Bjorkstrom NK; Stralin K; Llewellyn-Lacey S; Price DA; Qin C; Grifoni A; Weiskopf D; Wherry EJ; Sette A; Aleman S; Buggert M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;111(5):748-756

Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region

Andersson ML; Johansson H; Osterborg A; Mansson-Broberg A; Hansson L; Palma M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;111(5):715-721

Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients

Mattsson A; Sylvan SE; Axelsson P; Ellin F; Kjellander C; Larsson K; Lauri B; Lewerin C; Scharenberg C; Tatting L; Johansson H; Osterborg A; Hansson L
Article: EBIOMEDICINE. 2023;94:104700

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID

Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; oesterborg A; Smith CIE; Vesterbacka J; Wullimann D; Cuapio A; Akber M; Bogdanovic G; Muschiol S; aberg M; Lore K; Chen MS; Buggert M; Ljungman P; Aleman S; Ljunggren H-G
Article: JOURNAL OF HEMATOLOGY. 2023;12(4):170-175

Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia

Andersson M; Wu J; Wullimann D; Gao Y; Aberg M; Muschiol S; Healy K; Naud S; Bogdanovic G; Palma M; Mellstedt H; Chen P; Ljunggren H-G; Hansson L; Chen MS; Buggert M; Ingelman-Sundberg HM; Osterborg A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(21):3689-3699

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Munir T; Moreno C; Owen C; Follows G; Benjamini O; Janssens A; Levin M-D; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Niemann CUU; Kater APP
Article: SCIENCE TRANSLATIONAL MEDICINE. 2023;15(704):eadg9452

Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states

Muller TRR; Sekine T; Trubach D; Niessl J; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Olofsson A; Hernandez SPA; Gao Y; Cai C; Soderdahl G; Smith CIE; Osterborg A; Lore K; Sallberg Chen M; Ljungman P; Ljunggren H-G; Karlsson ACC; Saini SK; Aleman S; Buggert M
Article: BLOOD ADVANCES. 2023;7(12):2794-2806

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

Bonfiglio S; Sutton L-A; Ljungstrom V; Capasso A; Pandzic T; Westrom S; Foroughi-Asl H; Skaftason A; Gellerbring A; Lyander A; Gandini F; Gaidano G; Trentin L; Bonello L; Reda G; Bodor C; Stavroyianni N; Tam CS; Marasca R; Forconi F; Panayiotidis P; Ringshausen I; Jaksic O; Frustaci AM; Iyengar S; Coscia M; Mulligan SP; Ysebaert L; Strugov V; Pavlovsky C; Walewska R; Osterborg A; Cortese D; Ranghetti P; Baliakas P; Stamatopoulos K; Scarfo L; Rosenquist R; Ghia P
Article: PHARMACEUTICS. 2023;15(4):1148

A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells

Ghaderi A; Okhovat M-A; Lehto J; De Petris L; Doulabi EM; Kokhaei P; Zhong W; Rassidakis GZ; Drakos E; Moshfegh A; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(5):1035-1045

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

Hillmen P; Eichhorst B; Brown JR; Lamanna N; O'Brien SM; Tam CS; Qiu L; Kazmierczak M; Zhou K; Simkovic M; Mayer J; Gillespie-Twardy A; Shadman M; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Salmi T; Ji M; Yecies J; Idoine A; Wu K; Huang J; Jurczak W
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2023;388(4):319-332

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Brown JR; Eichhorst B; Hillmen P; Jurczak W; Kazmierczak M; Lamanna N; O'Brien SM; Tam CS; Qiu L; Zhou K; Simkovic M; Mayer J; Gillespie-Twardy A; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Salmi T; Wang M-D; Fu L; Li J; Wu K; Cohen A; Shadman M
Journal article: NEW ENGLAND JOURNAL OF MEDICINE. 2023;388(4):319-332

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Brown JR; Eichhorst B; Hillmen P; Jurczak W; Kazmierczak M; Lamanna N; O'Brien SM; Tam CS; Qiu L; Zhou K; Simkovic M; Mayer J; Gillespie-Twardy A; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Salmi T; Wang M-D; Fu L; Li J; Wu K; Cohen A; Shadman M
Article: LEUKEMIA RESEARCH. 2022;122:106945

Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study

Ma S; Rosen ST; Winqvist M; Frankfurt O; Winter JN; Gordon L; Helenowski I; Zhang H; Kreutzer J; Sonnert-Husa S; Osterborg A; Lundin J
Article: PHARMACEUTICS. 2022;14(10):2238

A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells

Ghaderi A; Zhong W; Okhovat MA; Aschan J; Svensson A; Sander B; Schultz J; Olin T; Osterborg A; Hojjat-Farsangi M; Mellstedt H
Article: IMMUNITY. 2022;55(9):1732-1746.e5

Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination

Gao Y; Cai C; Wullimann D; Niessl J; Rivera-Ballesteros O; Chen P; Lange J; Cuapio A; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Perez-Potti A; Sekine T; Muller TR; Boulouis C; Kammann T; Parrot T; Muvva JR; Sobkowiak M; Healy K; Bogdanovic G; Muschiol S; Soderdahl G; Osterborg A; Hellgren F; Grifoni A; Weiskopf D; Sette A; Lore K; Chen MS; Ljungman P; Sandberg JK; Smith CIE; Bergman P; Ljunggren H-G; Aleman S; Buggert M
Article: LANCET ONCOLOGY. 2022;23(8):1031-1043

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

Tam CS; Brown JR; Kahl BS; Ghia P; Giannopoulos K; Jurczak W; Simkovic M; Shadman M; Osterborg A; Laurenti L; Walker P; Opat S; Chan H; Ciepluch H; Greil R; Tani M; Trneny M; Brander DM; Flinn IW; Grosicki S; Verner E; Tedeschi A; Li J; Tian T; Zhou L; Marimpietri C; Paik JC; Cohen A; Huang J; Robak T; Hillmen P
Article: NEJM EVID. 2022;1(7):evidoa2200006

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.

Kater AP; Owen C; Moreno C; Follows G; Munir T; Levin M-D; Benjamini O; Janssens A; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Ysebaert L; Qin R; Steele AJ; Schuier N; Baeten K; Caces DB; Niemann CU
Article: NATURE MEDICINE. 2022;28(3):472-476

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant

Gao Y; Cai C; Grifoni A; Muller TR; Niessl J; Olofsson A; Humbert M; Hansson L; Osterborg A; Bergman P; Chen P; Olsson A; Sandberg JK; Weiskopf D; Price DA; Ljunggren H-G; Karlsson AC; Sette A; Aleman S; Buggert M
Article: CANCERS. 2022;14(5):1186

Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas

Xagoraris I; Farrajota Neves da Silva P; Kokaraki G; Stathopoulou K; Wahlin B; Osterborg A; Herold N; Ng S-B; Medeiros LJ; Drakos E; Sander B; Rassidakis GZ
Article: MED. 2022;3(2):137-153.e3

Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals

Healy K; Pin E; Chen P; Soderdahl G; Nowak P; Mielke S; Hansson L; Bergman P; Smith CIE; Ljungman P; Valentini D; Blennow O; Osterborg A; Gabarrini G; Al-Manei K; Alkharaan H; Sobkowiak MJ; Yousef J; Mravinacova S; Cuapio A; Xu X; Akber M; Lore K; Hellstrom C; Muschiol S; Bogdanovic G; Buggert M; Ljunggren H-G; Hober S; Nilsson P; Aleman S; Chen MS
Article: MOLECULAR MEDICINE. 2022;28(1):20

NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals

Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Potti AP; Ballesteros OR; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; Osterborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Lore K; Sobkowiak MJ; Gabarrini G; Healy K; Chen MS; Alici E; Bjorkstrom NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren H-G
Article: LEUKEMIA. 2022;36(2):476-481

Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients

Blixt L; Bogdanovic G; Buggert M; Gao Y; Hober S; Healy K; Johansson H; Kjellander C; Mravinacova S; Muschiol S; Nilsson P; Palma M; Pin E; Smith CIE; Stromberg O; Chen MS; Zain R; Hansson L; Osterborg A
Article: EBIOMEDICINE. 2021;74:103705

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Soderdahl G; Osterborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgstrom E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin A-C; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Lore K; Chen MS; Buggert M; Ljunggren H-G; Ljungman P; Aleman S
Article: BLOOD. 2021;138(18):1768-1773

COVID-19 in patients with CLL: improved survival outcomes and update on management strategies

Roeker LE; Eyre TA; Thompson MC; Lamanna N; Coltoff AR; Davids MS; Baker PO; Leslie L; Rogers KA; Allan JN; Cordoba R; Lopez-Garcia A; Antic D; Pagel JM; Martinez-Calle N; Antonio Garcia-Marco J; Hernandez-Rivas J-A; Miras F; Coombs CC; Osterborg A; Hansson L; Seddon AN; Lopez Jimenez J; Wilson MR; El-Sharkawi D; Wojenski D; Ma S; Munir T; Valenciano S; Seymour E; Barr PM; Pu J; Patten PEM; Perini GF; Huntington SF; Parry H; Sundaram S; Skarbnik A; Kamdar M; Jacobs R; Walter H; Walewska R; Broom A; Lebowitz S; Isaac KM; Portell CA; Ahn IE; Ujjani CS; Shadman M; Skanland S; Chong EA; Mato AR
Article: PROSTAGLANDINS & OTHER LIPID MEDIATORS. 2021;156:106575

Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells

Xia C; Sadeghi L; Straat K; Merrien M; Wright AP; Sander B; Xu D; Osterborg A; Bjorkholm M; Claesson H-E
Article: HAEMATOLOGICA. 2021;106(9):2354-2363

Zanubrutinib monotherapy for patients with treatment-naive chronic lymphocytic leukemia and 17p deletion

Tam CS; Robak T; Ghia P; Kahl BS; Walker P; Janowski W; Simpson D; Shadman M; Ganly PS; Laurenti L; Opat S; Tani M; Ciepluch H; Verner E; Simkovi M; Osterborg A; Trneny M; Tedeschi A; Paik JC; Kuwahara SB; Feng S; Ramakrishnan V; Cohen A; Huang J; Hillmen P; Brown JR
Article: EJHAEM. 2021;2(3):525-529

Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia

Lundin J; Mulder TA; Kattstrom M; Wasterlid T; Uddevik A; Mellstedt H; Heimersson K; Hansson L; Palma M; Osterborg A
Article: EJHAEM. 2021;2(3):498-502

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1⁺ CLL cells

Ghaderi A; Okhovat M-A; Wikanthi LSS; Svensson A; Palma M; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY. 2021;269:75-99

Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.

Hojjat-Farsangi M; Moshfegh A; Schultz J; Norin M; Olin T; Österborg A; Mellstedt H
Article: HAEMATOLOGICA. 2021;106(1):87-97

Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multicenter study

Leeksma AC; Baliakas P; Moysiadis T; Puiggros A; Plevova K; van der Kevie-Kersemaekers A-M; Posthuma H; Rodriguez-Vicente AE; Tran AN; Barbany G; Mansouri L; Gunnarsson R; Parker H; van den Berg E; Bellido M; Davis Z; Wall M; Scarpelli I; Osterborg A; Hansson L; Jarosova M; Ghia P; Poddighe P; Espinet B; Pospisilova S; Tam C; Ysebaert L; Nguyen-Khac F; Oscier D; Haferlach C; Schoumans J; Stevens-Kroef M; Eldering E; Stamatopoulos K; Rosenquist R; Strefford JC; Mellink C; Kater AP
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;191(3):426-432

Risk-adapted bendamustine plus rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients

Mattsson A; Sylvan SE; Asklid A; Wiggh J; Winqvist M; Lundin J; Mansouri L; Rosenquist R; Johansson H; Osterborg A; Hansson L
Article: BLOOD. 2020;136(10):1134-1143

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Mato AR; Roeker LE; Lamanna N; Allan JN; Leslie L; Pagel JM; Patel K; Osterborg A; Wojenski D; Kamdar M; Huntington SF; Davids MS; Brown JR; Antic D; Jacobs R; Ahn IE; Pu J; Isaac KM; Barr PM; Ujjani CS; Geyer MB; Berman E; Zelenetz AD; Malakhov N; Furman RR; Koropsak M; Bailey N; Hanson L; Perini GF; Ma S; Ryan CE; Wiestner A; Portell CA; Shadman M; Chong EA; Brander DM; Sundaram S; Seddon AN; Seymour E; Patel M; Martinez-Calle N; Munir T; Walewska R; Broom A; Walter H; El-Sharkawi D; Parry H; Wilson MR; Patten PEM; Hernandez-Rivas J-A; Miras F; Escalada NF; Ghione P; Nabhan C; Lebowitz S; Bhavsar E; Lopez-Jimenez J; Naya D; Garcia-Marco JA; Skanland SS; Cordoba R; Eyre TA
Article: LEUKEMIA & LYMPHOMA. 2020;61(9):2136-2144

A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy

Asklid A; Sylvan SE; Mattsson A; Winqvist M; Johansson H; Osterborg A; Hansson L
Article: BIOMEDICINES. 2020;8(6):E170-170

ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells

Ghaderi A; Daneshmanesh AH; Moshfegh A; Kokhaei P; Vagberg J; Schultz J; Olin T; Harrysson S; Smedby KE; Drakos E; Rassidakis GZ; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(4):689-693

Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report

Miklos U; Strugov V; Lewerin C; Grosicki S; Mazur G; Steurer M; Montillo M; Kryachok I; Middeke JM; Rekhtman G; Stefanelli T; Vincent G; Govindaraju S; Osterborg A
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2020;476:112675

Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies

Stasilojc G; Felberg A; Urban A; Kowalska D; Ma S; Blom AM; Lundin J; Osterborg A; Okroj M
Article: HAEMATOLOGICA. 2019;104(4):797-804

FFirst-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013

Sylvan SE; Asklid A; Johansson H; Klintman J; Bjellvi J; Tolvgard S; Kimby E; Norin S; Andersson P-O; Karlsson C; Karlsson K; Lauri B; Mattsson M; Sandstedt AB; Strandberg M; Osterborg A; Hansson L
Article: LEUKEMIA. 2018;32(10):2291-2295

First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells

Hojjat-Farsangi M; Daneshmanesh AH; Khan AS; Shetye J; Mozaffari F; Kharaziha P; Rathje L-S; Kokhaei P; Hansson L; Vagberg J; Bystrom S; Olsson E; Lofberg C; Norstrom C; Schultz J; Norin M; Olin T; Osterborg A; Mellstedt H; Moshfegh A
Article: ANNALS OF ONCOLOGY. 2018;29(Suppl 4):iv96-iv110

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

Aapro M; Beguin Y; Bokemeyer C; Dicato M; Gascon P; Glaspy J; Hofmann A; Link H; Littlewood T; Ludwig H; Osterborg A; Pronzato P; Santini V; Schrijvers D; Stauder R; Jordan K; Herrstedt J
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;183(2):212-224

Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes

Palma M; Krstic A; Perez LP; Bergloef A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Hoeglund P; Kimby E; OEsterborg A; Mansson R; Smith CIE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;182(4):504-512

Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials

Jones J; Mato A; Coutre S; Byrd JC; Furman RR; Hillmen P; Osterborg A; Tam C; Stilgenbauer S; Wierda WG; Heerema NA; Eckert K; Clow F; Zhou C; Chu AD; James DF; O'Brien SM
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;101(1):68-77

Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients

Palma M; Hansson L; Mulder TA; Adamson L; Nasman-Glaser B; Eriksson I; Heimersson K; Ryblom H; Mozaffari F; Svensson A; Gentilcore G; Osterborg A; Mellstedt H
Article: JOURNAL OF IMMUNOTHERAPY. 2018;41(2):73-83

CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN- Production Profile

Magalhaes I; Kalland I; Kochenderfer JN; Osterborg A; Uhlin M; Mattsson J
Article: PLOS ONE. 2018;13(6):e0198038

A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib

Daneshmanesh AH; Hojjat-Farsangi M; Ghaderi A; Moshfegh A; Hansson L; Schultz J; Vagberga J; Bystrom S; Olsson E; Olin T; Osterborg A; Mellstedt H
Article: PLOS ONE. 2018;13(2):e0192839

Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells

Kokhaei P; Hojjat-Farsangi M; Mozaffari F; Moshfegh A; Pak F; Rashidy-Pour A; Palma M; Hansson L; Osterborg A; Mellstedt H
Article: ONCOTARGET. 2017;8(61):103731-103743

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains

Alzrigat M; Parraga AA; Majumder MM; Ma A; Jin J; Osterborg A; Nahi H; Nilsson K; Heckman CA; Oberg F; Kalushkova A; Jernberg-Wiklund H
Article: ANNALS OF HEMATOLOGY. 2017;96(10):1681-1691

Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia

Hansson L; Asklid A; Diels J; Eketorp-Sylvan S; Repits J; Soltoft F; Jaeger U; Osterborg A
Article: HAEMATOLOGICA. 2017;102(3):562-572

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers

Palma M; Gentilcore G; Heimersson K; Mozaffari F; Nasman-Glaser B; Young E; Rosenquist R; Hansson L; Osterborg A; Mellstedt H
Article: ONCOTARGET. 2017;8(6):10213-10224

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions

Alzrigat M; Parraga AA; Agarwal P; Zureigat H; Osterborg A; Nahi H; Ma A; Jin J; Nilsson K; Oberg F; Kalushkova A; Jernberg-Wiklund H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2017;66(1):91-102

Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints

Winqvist M; Mozaffari F; Palma M; Sylvan SE; Hansson L; Mellstedt H; Osterborg A; Lundin J
Article: HAEMATOLOGICA. 2016;101(12):1573-1580

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group

Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Osterborg A
Article: ONCOLOGY LETTERS. 2016;12(4):2782-2788

Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions

Hogfeldt T; Jaing C; Mc Loughlin K; Thissen J; Gardner S; Bahnassy AA; Gharizadeh B; Lundahl J; Osterborg A; Porwit A; Zekri A-RN; Khaled HM; Mellstedt H; Moshfegh A
Article: LANCET ONCOLOGY. 2016;17(10):1409-1418

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Osterborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Article: LEUKEMIA & LYMPHOMA. 2016;57(9):2037-2046

Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia

Osterborg A; Udvardy M; Zaritskey A; Andersson P-O; Grosicki S; Mazur G; Kaplan P; Steurer M; Schuh A; Montillo M; Kryachok I; Middeke JM; Kulyaba Y; Rekhtman G; Gorczyca M; Daly S; Chang C-N; Lisby S; Gupta I
Article: TUMOR BIOLOGY. 2016;37(9):11947-11957

Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia

Khan AS; Hojjat-Farsangi M; Daneshmanesh AH; Hansson L; Kokhaei P; Osterborg A; Mellstedt H; Moshfegh A
Article: ONCOTARGET. 2016;7(6):6809-6823

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target

Agarwal P; Alzrigat M; Parraga AA; Enroth S; Singh U; Ungerstedt J; Osterborg A; Brown PJ; Ma A; Jin J; Nilsson K; Oberg F; Kalushkova A; Jernberg-Wiklund H
Article: EXPERIMENTAL HEMATOLOGY. 2016;44(1):38-49.e1

Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study

Sylvan SE; Skribek H; Norin S; Muhari O; Osterborg A; Szekely L
Article: MOLECULAR IMMUNOLOGY. 2015;66(2):164-170

Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation

Blom AM; Osterborg A; Mollnes TE; Okroj M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2015;170(1):40-49

Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients

Osterborg A; Wierda WG; Mayer J; Hess G; Hillmen P; Schetelig J; Schuh A; Smolej L; Beck C; Dreyfus B; Hellman A; Kozlowski P; Pfreundschuh M; Rizzi R; Spacek M; Phillips JL; Gupta IV; Williams V; Jewell RC; Nebot N; Lisby S; Dyer MJS
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2015;45(6):1783-1793

Dendritic cell regulation of NK-cell responses involves lymphotoxin-, IL-12, and TGF-

Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Osterborg A; Lundqvist A
Article: FUTURE ONCOLOGY. 2015;11(1):51-59

The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia

Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Article: PLOS ONE. 2015;10(11):e0142310

Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia

Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Osterborg A; Mellstedt H; Shokri F
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2014;10(11):3394-3408

Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study

Rossmann E; Osterborg A; Lofvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schroeder A; Mellstedt H
Article: SUPPORTIVE CARE IN CANCER. 2014;22(8):2197-2206

A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia

Ludwig H; Aapro M; Bokemeyer C; Glaspy J; Hedenus M; Littlewood TJ; Osterborg A; Rzychon B; Mitchell D; Beguin Y
Article: LEUKEMIA & LYMPHOMA. 2014;55(8):1774-1780

Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region

Sylvan SE; Hansson L; Karlsson C; Norin S; Lundin J; Osterborg A
Article: JOURNAL OF CLINICAL PHARMACOLOGY. 2014;54(7):818-827

Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis

Struemper H; Sale M; Patel BR; Ostergaard M; Osterborg A; Wierda WG; Hagenbeek A; Coiffier B; Jewell RC
Article: LEUKEMIA & LYMPHOMA. 2014;55(5):1158-1165

Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas

Hoegfeldt T; Johnsson P; Grander D; Bahnassy AA; Porwit A; Eid S; Osterborg A; Zekri A-RN; Lundahl J; Khaled MH; Mellstedt H; Moshfegh A
Article: MEDICAL ONCOLOGY. 2013;30(4):759

Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement

Okroj M; Eriksson I; Osterborg A; Blom AM
Article: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2013;2(1):23

Opticin, a small leucine-rich proteoglycan, is uniquely expressed and translocated to the nucleus of chronic lymphocytic leukemia cells.

Mikaelsson E; Osterborg A; Tahmasebi Fard Z; Mahmoudi A; Mahmoudian J; Jeddi-Tehrani M; Akhondi M; Shokri F; Bishop PN; Rabbani H; Mellstedt H
Article: EXPERIMENTAL HEMATOLOGY. 2013;41(7):615-626

Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia

Palma M; Parker A; Hojjat-Farsangi M; Forster J; Kokhaei P; Hansson L; Osterborg A; Mellstedt H
Article: LEUKEMIA & LYMPHOMA. 2013;54(5):996-1003

Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures

Hogfeldt T; Bahnassy AA; Kwiecinska A; Osterborg A; Tamm KP; Porwit A; Zekri A-RN; Lundahl J; Khaled HM; Mellstedt H; Moshfegh A
Article: LEUKEMIA & LYMPHOMA. 2013;54(4):843-850

Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies

Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grander D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Osterborg A
Article: EXPERIMENTAL CELL RESEARCH. 2013;319(5):600-611

An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma

Lin H; Kolosenko I; Bjorklund A-C; Protsyuk D; Osterborg A; Grander D; Tamm KP
Article: PLOS ONE. 2013;8(10):e78339

The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells

Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Osterborg A; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2013;62(1):51-63

T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile

Kiaii S; Kokhaei P; Mozaffari F; Rossmann E; Pak F; Moshfegh A; Palma M; Hansson L; Mashayekhi K; Hojjat-Farsangi M; Osterborg A; Choudhury A; Mellstedt H
Article: PLOS ONE. 2013;8(6):e67601

A Proline/Arginine-Rich End Leucine-Rich Repeat Protein (PRELP) Variant Is Uniquely Expressed in Chronic Lymphocytic Leukemia Cells

Mikaelsson E; Osterborg A; Jeddi-Tehrani M; Kokhaei P; Ostadkarampour M; Hadavi R; Gholamin M; Akhondi M; Shokri F; Rabbani H; Mellstedt H
Article: LEUKEMIA & LYMPHOMA. 2012;53(11):2151-2158

Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis

Hedenus M; Oesterborg A; Tomita D; Bohac C; Coiffier B
Article: CANCER RESEARCH. 2012;72(20):5348-5362

Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model

Kharaziha P; De Raeve H; Fristedt C; Li Q; Gruber A; Johnsson P; Kokaraki G; Panzar M; Laane E; Osterborg A; Zhivotovsky B; Jernberg-Wiklund H; Grander D; Celsing F; Bjorkholm M; Vanderkerken K; Panaretakis T
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(25):3093-3099

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Osterborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Ostenstad B; Fagerli U-M; Gadeberg OV; Sundstrom C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
Article: LEUKEMIA. 2012;26(6):1348-1355

Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells

Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi A-R; Hadavi R; Osterborg A; Shokri F; Rabbani H; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(6):865-879

Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria

Palma M; Hansson L; Choudhury A; Nasman-Glaser B; Eriksson I; Adamson L; Rossmann E; Widen K; Horvath R; Kokhaei P; Vertuani S; Mellstedt H; Osterborg A
Article: CLINICAL CANCER RESEARCH. 2012;18(8):2230-2239

The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin

Lemaire M; Fristedt C; Agarwal P; Menu E; Van Valckenborgh E; De Bruyne E; Osterborg A; Atadja P; Larsson O; Axelson M; Van Camp B; Jernberg-Wiklund H; Vanderkerken K
Article: MEDICAL ONCOLOGY. 2011;28(4):1210-1217

Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies

de Boer R; Clemens M; Renczes G; Kotasek D; Prausova J; Marschner N; Hedenus M; Doshi S; Hendricks L; Osterborg AC
Article: BLOOD. 2011;118(19):5126-5129

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

Wierda WG; Padmanabhan S; Chan GW; Gupta IV; Lisby S; Osterborg A
Article: LANCET ONCOLOGY. 2011;12(11):1013-1022

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Pfreundschuh M; Kuhnt E; Truemper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani P-L; Shpilberg O; Kvaloy S; Brown PDN; Stahel R; Milpied N; Lopez-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N
Article: ANNALS OF ONCOLOGY. 2011;22(3):664-670

Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study

Rieger M; Osterborg A; Pettengell R; White D; Gill D; Walewski J; Kuhnt E; Loeffler M; Pfreundschuh M; Ho AD
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2010;151(4):327-335

Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells

Choudhury A; Derkow K; Daneshmanesh AH; Mikaelsson E; Kiaii S; Kokhaei P; Osterborg A; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2010;150(5):565-573

Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma

d'Amore F; Radford J; Relander T; Jerkeman M; Tilly H; Osterborg A; Morschhauser F; Gramatzki M; Dreyling M; Bang B; Hagberg H
Article: PLOS ONE. 2010;5(7):e11483

Polycomb Target Genes Are Silenced in Multiple Myeloma

Kalushkova A; Fryknas M; Lemaire M; Fristedt C; Agarwal P; Eriksson M; Deleu S; Atadja P; Osterborg A; Nilsson K; Vanderkerken K; Oberg F; Jernberg-Wiklund H
Article: JOURNAL OF CLINICAL ONCOLOGY. 2010;28(10):1749-1755

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJS; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Oesterborg A
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2010;10(3):439-449

Ofatumumab, a human anti-CD20 monoclonal antibody

Osterborg A
Article: CLINICAL ADVANCES IN HEMATOLOGY AND ONCOLOGY. 2010;8(1):28-30

Advances in LLM. Ofatumumab: a new agent for chronic lymphocytic leukemia.

Osterborg A
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2009;69(6):529-536

Generation of a Dendritic Cell-based Vaccine in Chronic Lymphocytic Leukaemia Using CliniMACS Platform for Large-scale Production

Adamson L; Palma M; Choudhury A; Eriksson I; Nasman-Glaser B; Hansson M; Hansson L; Kokhaei P; Osterborg A; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(1):111-120

Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study

Mozaffari F; Lindemalm C; Choudhury A; Granstam-Bjorneklett H; Lekander M; Nilsson B; Ojutkangas M-L; Osterborg A; Bergkvist L; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2009;144(1):78-85

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia

Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
Article: INTERNATIONAL JOURNAL OF CANCER. 2008;123(5):1190-1195

Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy

DaneshManesh AH; Mikaelsson E; Jeddi-Tehrani M; Bayat AA; Ghods R; Ostadkarampour M; Akhondi M; Lagercrantz S; Larsson C; Osterborg A; Shokri F; Mellstedt H; Rabbani H
Article: ANNALS OF ONCOLOGY. 2008;19(6):1172-1179

Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC)

Abdalla AO; Kokhaei P; Hansson L; Mellstedt H; Osterborg A
Article: INVESTIGATIONAL NEW DRUGS. 2008;26(2):139-149

Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia

Jensen M; Engert A; Weissinger F; Knauf W; Kimby E; Poynton C; Oliff IA; Rummel MJ; Oesterborg A
Article: LEUKEMIA & LYMPHOMA. 2008;49(1):102-112

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a:: A randomized phase II study from the Nordic Lymphoma Group

Kimby E; Jurlander J; Geisler C; Hagberg H; Holte H; Lehtinen T; Oestenstad B; Hansen M; Oesterborg A; Linden O; Sundstroem C
Article: ACTA ONCOLOGICA. 2008;47(6):1009-1017

The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia:: A Markov model

Borg S; Glenngard AH; Osterborg A; Persson U
Article: SUPPORTIVE CARE IN CANCER. 2008;16(1):57-65

Immune response, depression and fatigue in relation to support intervention in mammary cancer patients

Lindemalm C; Mozaffari F; Choudhury A; Granstam-Bjorneklett H; Lekander M; Nilsson B; Ojutkangas M-L; Osterborg A; Bergkvist L; Mellstedt H
Article: CYTOMETRY PART B-CLINICAL CYTOMETRY. 2007;72B(6):450-457

Performance of calibration standards for antigen quantitation with flow cytometry chronic lymphocytic leukemia

Rossmann ED; Lenkei R; Lundin J; Mellstedt H; Oesterborg A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2007;79(5):371-381

Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients

Abdalla AO; Hansson L; Eriksson I; Nasman-Glaser B; Mellstedt H; Osterborg A
Article: BRITISH JOURNAL OF CANCER. 2007;97(6):769-777

Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia

Olsson A; Norberg M; Okvist A; Derkow K; Choudhury A; Tobin G; Celsing F; Osterborg A; Rosenquist R; Jondal M; Osorio LM
Article: MEDICAL ONCOLOGY. 2007;24(3):267-272

Erythropoietin therapy and cancer related anaemia:: updated Swedish recommendations

Ahlqvist-Rastad J; Albertsson M; Bergh J; Birgegard G; Johansson P; Jonsson B; Kjellen E; Pahlman S; Zackrisson B; Osterborg A
Article: BRITISH JOURNAL OF CANCER. 2007;97(1):105-111

NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy

Mozaffari F; Lindemalm C; Choudhury A; Granstam-Bjorneklett H; Helander I; Lekander M; Mikaelsson E; Nilsson B; Ojutkangas M-L; Osterborg A; Bergkvist L; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 2007;13(12):3536-3544

Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies

Kokhaei P; Abdalla AO; Hansson L; Mikaelsson E; Kubbies M; Haselbeck A; Jernberg-Wiklund H; Mellstedt H; Osterborg A
Article: BLOOD. 2007;109(11):4655-4662

Clinical efficacy of zanolimumab (HuMax-CD4):: two phase 2 studies in refractory cutaneous T-cell lymphoma

Kim YH; Duvic M; Obitz E; Gniadecki R; Iversen L; Osterborg A; Whittaker S; Illidge TM; Schwarz T; Kaufmann R; Cooper K; Knudsen KM; Lisby S; Baadsgaard O; Knox SJ
Article: LEUKEMIA. 2007;21(4):627-632

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies:: a randomized multicenter study

Hedenus M; Birgegard G; Nasman P; Ahlberg L; Karlsson T; Lauri B; Lundin J; Larfars G; Osterborg A
Article: CLINICAL CANCER RESEARCH. 2007;13(5):1503-1510

Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients

Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2007;136(5):736-744

Phase II study of three dose levels of continuous erythropoietin receptor activator (CERA) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy

Osterborg A; Steegmann JL; Hellmann A; Couban S; Mayer J; Eid JE
Article: EXPERIMENTAL HEMATOLOGY. 2007;35(2):297-304

Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells

Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Article: HAEMATOLOGICA. 2007;92(1):110-114

Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma -: evaluation of T-cell responses by different read-out systems

Abdalla AO; Hansson L; Eriksson I; Nasman-Glaser B; Rossmann ED; Rabbani H; Mellstedt H; Osterborg A
Article: BRITISH JOURNAL OF CANCER. 2006;95(11):1467-1473

Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer:: a meta-analysis

Aapro M; Coiffier B; Dunst J; Osterborg A; Burger HU
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;135(4):475-485

Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia

Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Article: LEUKEMIA & LYMPHOMA. 2006;47(7):1229-1238

Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia:: long-term effects of fludarabine and alemtuzumab treatment

Kiaii S; Choudhury A; Mozaffari F; Rezvany R; Lundin J; Mellstedt H; Osterborg A
Article: LANCET ONCOLOGY. 2006;7(5):379-391

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group

Pfreundschuh M; Trumper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani P-L; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; Lopez-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M
Article: BLOOD. 2006;107(2):669-678

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G₂/M-phase accumulation and apoptosis in multiple myeloma cells

Strömberg T; Ekman S; Girnita L; Dimberg LY; Larsson O; Axelson M; Lennartsson J; Hellman U; Carlson K; Österborg A; Vanderkerken K; Nilsson K; Jernberg-Wiklund H
Article: CYTOTHERAPY. 2006;8(4):318-326

Generation of DC-based vaccine for therapy of B-CLL patients.: Comparison of two methods for enriching monocytic precursors

Kokhaei P; Adamson L; Palma M; Osterborg A; Pisa P; Choudhury A; Mellstedt H
Article: BLOOD. 2005;106(4):1346-1354

Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells

Dimberg LY; Dimberg AI; Ivarsson K; Strömberg T; Österborg A; Nilsson K; Öberg F; Wiklund HJ
Article: BLOOD. 2005;105(12):4828-4835

Fibromodulin, an extracellular matrix protein:: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma

Mikaelsson E; Danesh-Manesh AH; Lüppert A; Jeddi-Tehrani M; Rezvany MR; Sharifian RA; Safaie R; Roohi A; Österborg A; Shokri F; Mellstedt H; Rabbani H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2005;129(2):206-209

Impact of epoetin-β on survival of patients with lymphoproliferative malignancies:: long-term follow up of a large randomized study

Österborg A; Brandberg Y; Hedenus M
Article: INTERNATIONAL JOURNAL OF CANCER. 2005;113(5):730-737

High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia

Morales AA; Olsson A; Celsing F; Österborg A; Jondal M; Osorio LM
Article: MEDICAL ONCOLOGY. 2005;22(3):291-302

Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL) comparison of indolent and progressive disease

Kiaii S; Choudhury A; Mozaffari F; Kimby E; Österborg A; Mellstedt M
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2004;33(6):423-427

Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone

van Vollenhoven RF; Gunnarsson I; Welin-Henriksson E; Sundelin B; Österborg A; Jacobson SH; Klareskog L
Article: LEUKEMIA. 2004;18(11):1810-1815

Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL

Kokhaei P; Choudhury A; Mahdian R; Lundin J; Moshfegh A; Österborg A; Mellstedt H
Article: EUROPEAN JOURNAL OF CANCER. 2004;40(15):2201-2216

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer

Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Österborg A; Repetto L; Soubeyran P
Article: BLOOD. 2004;104(4):948-955

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

Hale G; Rebello P; Brettman LR; Fegan C; Kennedy B; Kimby E; Leach M; Lundin J; Mellstedt H; Moreton P; Rawstron AC; Waldmann H; Osterborg A; Hillmen P
Article: SEMINARS IN HEMATOLOGY. 2004;41(3):234-245

Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia

Lundin J; Österborg A
Article: BLOOD. 2004;103(8):3138-3147

Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone

Strömberg T; Dimberg A; Hammarberg A; Carlson K; Österborg A; Nilsson K; Jernberg-Wiklund H
Article: BLOOD. 2004;103(8):2920-2924

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

Enblad G; Hagberg H; Erlanson M; Lundin J; MacDonald AP; Repp R; Schetelig J; Seipelt G; Österborg A
Article: LEUKEMIA. 2004;18(3):484-490

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Österborg A; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;124(3):315-324

Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage

Mozaffari F; Hansson L; Kiaii S; Ju XL; Rossmann ED; Rabbani H; Mellstedt H; Österborg A
Article: LEUKEMIA. 2004;18(1):41-47

Expression and transcriptional regulation of functionally distinct Bmf isoforms in B-chronic lymphocytic leukemia cells

Morales AA; Olsson A; Celsing F; Österborg A; Jondal M; Osorio LM
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2003;58(6):601-606

Kinetics of cytokine gene expression in human CD4⁺ and CD8⁺ T-lymphocyte subsets using quantitative real-time PCR

Abdalla AO; Kiaii S; Hansson L; Rossmann ED; Jeddi-Tehrani M; Shokri F; Österborg A; Mellstedt H; Rabbani H
Article: BLOOD. 2003;101(12):4930-4936

T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma

Hansson L; Rabbani H; Fagerberg J; Österborg A; Mellstedt K
Article: BLOOD. 2003;101(11):4607-4610

Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells

Rasmussen T; Hansson L; Österborg A; Johnsen HE; Mellstedt H
Article: BLOOD. 2003;101(11):4267-4272

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

Lundin J; Hagberg H; Repp R; Cavallin-Stahl E; Fredén S; Juliusson G; Rosenblad E; Tjonnfjord G; Wiklund T; Österborg A
Article: LEUKEMIA. 2003;17(5):894-899

Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL

Kokhaei P; Rezvany MR; Virving L; Choudhury A; Rabbani H; Österborg A; Mellstedt H
Article: BLOOD. 2003;101(3):1063-1070

Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia

Rezvany MR; Jeddi-Tehrani M; Wigzell H; Österborg A; Mellstedt H
Article: HEMATOLOGY JOURNAL. 2003;4(4):248-252

Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.

Lundin J; Osterborg A; Björkholm M; Björkstrand B; Celsing F; Hjalmar V; Linder O; Luthman M; Merup M; Tidefelt U; Mellstedt H; Myeloma Group of Central Sweden
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2002;119(1):79-86

Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies

Hedenus M; Hansen S; Taylor K; Arthur C; Emmerich B; Dewey C; Watson D; Rossi G; Österborg A
Article: BLOOD. 2002;100(3):768-773

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Österborg A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2002;20(10):2486-2494

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies

Österborg A; Brandberg Y; Molostova V; Iosava G; Abdulkadyrov K; Hedenus M; Messinger D
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2002;68(5):299-306

Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL)

Rossmann ED; Lewin N; Jeddi-Tehrani M; Österborg A; Mellstedt H
Article: MEDICAL ONCOLOGY. 2002;19(4):277-280

Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia

Cavalli-Björkman N; Ösby E; Lundin J; Kalin M; Österborg A; Gruber A
Article: MEDICAL ONCOLOGY. 2002;19:S21-S26

Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia

Osterborg A; Mellstedt H; Keating M
Article: LEUKEMIA. 2001;15(12):1868-1877

Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D

Olsson A; Diaz T; Aguilar-Santelises M; Österborg A; Celsing F; Jondal M; Osorio LM
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;115(2):263-271

Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern

Rezvany MR; Jeddi-Tehrani M; Biberfeld P; Söderlund J; Mellstedt H; Österborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;113(4):1020-1034

Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.

Myeloma Trialists' Collaborative Group
Article: INTERNATIONAL JOURNAL OF CANCER. 2001;95(3):184-188

Interleukin-10 gene promoter polymorphisms in multiple myeloma

Zheng C; Huang DR; Liu L; Wu RH; Glas SB; Österborg A; Björkholm M; Holm G; Yi Q; Sundblad A
Article: CLINICAL IMMUNOLOGY. 2001;99(1):65-74

Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation

Ullenhag G; Bird C; Ragnhammar P; Frödin JE; Strigård K; Österborg A; Thorpe R; Mellstedt H; Wadhwa M
Article: HEMATOLOGY JOURNAL. 2001;2(5):300-306

Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies.

Rossmann ED; Lundin J; Lenkei R; Mellstedt H; Osterborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;112(1):155-160

Interleukin 4 therapy for patients with chronic lymphocytic leukaemia:: a phase I/II study

Lundin J; Kimby E; Bergmann L; Karakas T; Mellstedt H; Österborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;111(2):608-617

Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia

Rezvany MR; Jeddi-Tehrani M; Rabbani H; Lewin N; Avila-Cariño J; Österborg A; Wigzell H; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;111(1):230-238

Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia

Rezvany MR; Jeddi-Tehrani M; Rabbani H; Rudén U; Hammarström L; Österborg A; Wigzell H; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;109(1):39-45

Interleulkin 6, tumour necrosis factor α, interleukin 1β and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma

Zheng CY; Huang DR; Bergenbrant S; Sundblad A; Österborg A; Björkholm M; Holm G; Yi Q
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1999;63(3):163-170

The influence of interferon-α on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma

Hassan M; Nilsson C; Olsson H; Lundin J; Österborg A
Article: BLOOD. 1999;94(3):1063-1069

Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia:: Major perturbations are preferentially seen within the CD4 T-Cell subset

Rezvany MR; Jeddi-Tehrani M; Österborg A; Kimby E; Wigzell H; Mellstedt H
Article: EUROPEAN JOURNAL OF CANCER. 1999;35:S29-S32

Local low-dose of soluble GM-CSF significantly augments an immune response against tumour antigens in man

Mellstedt H; Fagerberg J; Österborg A
Article: INTERNATIONAL JOURNAL OF CANCER. 1999;80(5):671-680

T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma

Fagerberg J; Yi Q; Gigliotti D; Harmenberg U; Rudén U; Persson B; Österborg A; Mellstedt H
Article: PATHOLOGIE ET BIOLOGIE. 1999;47(2):211-215

Active idiotype vaccination in multiple myeloma -: GM-CSF may be an important adjuvant cytokine

Mellstedt H; Österborg A
Article: JOURNAL OF CLINICAL ONCOLOGY. 1998;16(12):3832-3842

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Article: JOURNAL OF CLINICAL ONCOLOGY. 1998;16(10):3257-3263

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas:: A phase II multicenter study

Lundin J; Österborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
Article: BLOOD. 1998;92(2):402-404

Blood dendritic cells from myeloma patients are not infected with Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)

Yi Q; Ekman M; Anton D; Bergenbrant S; Österborg A; Georgii-Hemming P; Holm G; Nilsson K; Biberfeld P
Article: BLOOD. 1998;92(1):68-75

Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin:: Results from a randomized phase II study and long-term follow-up of 71 patients

Hellström-Lindberg E; Ahlgren T; Beguin Y; Carlsson M; Carneskog J; Dahl IM; Dybedal I; Grimfors G; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Nilsson-Ehle H; Samuelsson J; Tangen JM; Winqvist I; Öberg G; Österborg A; Öst Å
Article: BLOOD. 1998;91(7):2459-2466

Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses

Österborg A; Yi Q; Henriksson L; Fagerberg J; Bergenbrant S; Jeddi-Tehrani M; Rudén U; Lefvert AK; Holm G; Mellstedt H
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1997;27(9):2245-2252

T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8(+) T cell expansions are found preferentially in patients with a low tumor burden

Halapi E; Werner A; Wahlstrom J; Osterborg A; JeddiTehrani M; Yi Q; Janson CH; Wigzell H; Grunewald J; Mellstedt H
Article: BLOOD. 1997;90(5):1960-1967

Myeloma bone marrow plasma cells: Evidence for their capacity as antigen-presenting cells

Yi Q; Dabadghao S; Osterborg A; Bergenbrant S; Holm G
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1997;234(2):296-299

Activities of vitamin Q(10) in animal models and a serious deficiency in patients with cancer

Folkers K; Osterborg A; Nylander M; Morita M; Mellstedt H
Article: JOURNAL OF CLINICAL ONCOLOGY. 1997;15(4):1567-1574

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia

Osterborg A; Dyer MJS; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H; Rankin E; Tsekouras C; Pangalis GA; Cavalli F; Sessa C; Huhn D; Marcus R; Maughan T; Poynton C; Nissen N; Carney D; Brittinger G; Uppenkamp M; Elonen E; Teerenhovi L; Engert; Willemze R; KluinNelemans J; Thomas J; Epenetos AA; Nethersell A; Dyer M; Catovsky D; Dicato M; Bastion Y; Coiffier B; Ranada JMF; Crowther D; Woll P; Raemakaers J; dePauw B; Degos L; Gissellbrecht; Reiffers J; Mellstedt H; Fassas A; Anagnostopoulos A; Bunjes D; Jaeger U; Stahel RA
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1997;96(2):338-345

Idiotype-specific T lymphocytes in monoclonal gammopathies: Evidence for the presence of CD4(+) and CD8(+) subsets

Yi Q; Eriksson I; He W; Holm G; Mellstedt H; Osterborg A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1997;58(1):5-13

Clonal CD8(+) and CD52(-) T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52)

Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;94(3):425-432

Cytokine therapy in multiple myeloma.

Peest D; Bladé J; Harousseau JL; Klein B; Osterborg A; San Miguel JF
Article: BLOOD. 1996;87(7):2675-2682

Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized multicenter study

Osterborg A; Boogaerts MA; Cimino R; Essers U; Holowiecki J; Juliusson G; Jager G; Najman A; Peest D
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;93(1):151-153

Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia

Osterborg A; Fassas AS; Anagnostopoulos A; Dyer MJS; Catovsky D; Mellstedt H
Article: MEDICAL ONCOLOGY. 1996;13(1):1-7

Idiotype-specific T cells in multiple myeloma: Targets for an immunotherapeutic intervention?

Yi Q; Osterborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;92(4):840-846

Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients

Bergenbrant S; Yi Q; Osterborg A; Bjorkholm M; Osby E; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;92(1):71-76

Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): Association with malignant transformation

Isaksson E; Bjorkholm M; Holm G; Johansson B; Nilsson B; Mellstedt H; Osterborg A
Article: BLOOD. 1995;86(8):3043-3049

IDIOTYPE-REACTIVE T-CELL SUBSETS AND TUMOR LOAD IN MONOCLONAL GAMMOPATHIES

YI Q; OSTERBORG A; BERGENBRANT S; MELLSTEDT H; HOLM G; LEFVERT AK
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;63(2):190-192

RESPONSE TO INTERFERON THERAPY IN PATIENTS WITH MULTIPLE-MYELOMA CORRELATES WITH EXPRESSION OF THE BCL-2 ONCOPROTEIN

SANGFELT O; OSTERBORG A; GRANDER D; ANDERBRING E; OST A; MELLSTEDT H; EINHORN S
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1995;89(1):110-116

IDIOTYPE-SPECIFIC T-CELLS IN MULTIPLE-MYELOMA STAGE-I - AN EVALUATION BY 4 DIFFERENT FUNCTIONAL TESTS

OSTERBORG A; YI Q; BERGENBRANT S; HOLM G; LEFVERT AK; MELLSTEDT H
Visa fler

Alla övriga publikationer

Editorial comment: FUTURE ONCOLOGY. 2024;20(12):717-726

Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment

Brown JR; Eichhorst B; Hillmen P; Jurczak W; Kazmierczak M; Lamanna N; O'Brien SM; Tam CS; Qiu L; Zhou K; Simkovic M; Mayer J; Gillespie-Twardy A; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Salmi T; Wang M-D; Fu L; Li J; Wu K; Cohen A; Shadman M
Letter: HAEMATOLOGICA. 2024;109(2):646-651

Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia

Ingelman-Sundberg HM; Blixt L; Wullimann D; Wu J; Gao Y; Healy K; Muschiol S; Bogdanovic G; Aberg M; Kjellander C; Grifoni A; Sette A; Aleman S; Chen P; Blennow O; Hansson L; Ljunggren H-G; Chen MS; Buggert M; Osterborg A
Letter: ACTA ONCOLOGICA. 2023;62(6):560-564

The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results

Smedby KE; Waesterlid T; Tham E; Haider Z; Joelsson J; Thorvaldsdottir B; Krstic A; Wahlin BE; Foroughi-Asl H; Karlsson C; Eloranta S; Saft L; Palma M; Kwiecinska A; Hansson L; Osterborg A; Wirta V; Rassidakis G; Sander B; Sonnevi K; Rosenquist R
Letter: BLOOD. 2022;140(22):2403-2407

Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination

Blixt L; Gao Y; Wullimann D; Ingelman-Sundberg HM; Muschiol S; Healy K; Bogdanovic G; Pin E; Nilsson P; Kjellander C; Grifoni A; Sette A; Chen MS; Ljunggren H-G; Buggert M; Hansson L; Osterborg A
Review: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2022;95(4):e13153

Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?

Smith CIE; Zain R; osterborg A; Palma M; Buggert M; Bergman P; Bryceson Y
Letter: HAEMATOLOGICA. 2022;107(4):1000-1003

T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial

Blixt L; Wullimann D; Aleman S; Lundin J; Chen P; Gao Y; Cuapio A; Akber M; Lange J; Rivera-Ballesteros O; Buggert M; Ljunggren H-G; Hansson L; Osterborg A
Review: FRONTIERS IN IMMUNOLOGY. 2021;12:686768

BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects

Palma M; Mulder TA; Osterborg A
Review: CANCERS. 2019;11(7):E915-915

Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application

Mulder TA; Wahlin BE; Osterborg A; Palma M
Letter: HAEMATOLOGICA. 2019;104(5):e208-e210

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort

Winqvist M; Andersson P-O; Asklid A; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Rosenquist R; Spath F; Hansson L; Osterborg A
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2019;185(1):179-183

HAX-1 overexpression in multiple myeloma is associated with poor survival

Feng X; Kwiecinska A; Rossmann E; Bottai M; Ishikawa T; Patarroyo M; Osterborg A; Porwit A; Zheng C; Fadeel B
Meeting abstract: BLOOD. 2018;132:5569

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

Miklos U; Strugov V; Lewerin C; Grosicki S; Mazur G; Steurer M; Montillo M; Kryachok I; Middeke JM; Rekhtman G; Stefanelli T; Vincent G; Sameera G; Osterborg A
Meeting abstract: BLOOD. 2018;132:2868

Genetic Basis, Expression Patterns and Clinical Significance of PD-L1 in Peripheral T-Cell Lymphomas (PTCL)

Da Silva PFN; Atsaves V; Tsesmetzis N; Kokaraki G; Osterborg A; Rassidakis G
Meeting abstract: BLOOD. 2018;132:4421

Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatement in Relapsed or Refactory Chronic Lymphocytic Leukemia Patients

Palma M; Heimersson K; Mulder TA; Nasman-Glaser B; Osterborg A; Mellstedt H
Meeting abstract: BLOOD. 2018;132:4130

The Novel Tumor Suppressor SAMHD1 Is Differentially Expressed and Partly Regulated By MYC in Peripheral T-Cell Lymphomas (PTCL)

Da Silva PFN; Tsesmetzis N; Xagoraris I; Wasik AM; Kokaraki G; Tzoras E; Osterborg A; Sander B; Herold N; Rassidakis G
Corrigendum: ANNALS OF ONCOLOGY. 2018;29(Suppl 4):iv271

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.

Aapro M; Beguin Y; Bokemeyer C; Dicato M; Gascón P; Glaspy J; Hofmann A; Link H; Littlewood T; Ludwig H; Österborg A; Pronzato P; Santini V; Schrijvers D; Stauder R; Jordan K; Herrstedt J; ESMO Guidelines Committee
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2018;182(4):590-594

Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study

Winqvist M; Palma M; Heimersson K; Mellstedt H; OEsterborg A; Lundin J
Meeting abstract: MOLECULAR IMMUNOLOGY. 2017;89:203

Monitoring of hemolytic activity of serum during alemtuzumab/ofatumumab therapy of chronic lymphocytic leukemia

Stasilojc G; Winqvist M; Blorn A; Osterborg A; Okroj M
Letter: LEUKEMIA & LYMPHOMA. 2017;58(5):1219-1223

Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013

Asklid A; Winqvist M; Sylvan SE; Mattsson A; Bjorgvinsson E; Soltoft F; Repits J; Diels J; Osterborg A; Hansson L
Review: ANNALS OF ONCOLOGY. 2017;28(2):218-227

Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force

Stauder R; Eichhorst B; Hamaker ME; Kaplanov K; Morrison VA; Osterborg A; Poddubnaya I; Woyach JA; Shanafelt T; Smolej L; Ysebaert L; Goede V
Meeting abstract: BLOOD. 2016;128(22):2038

Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study

Mauro FR; Tedeschi A; Piciocchi A; Motta M; Iannella E; Farina L; Scarfo L; Marasca R; Coscia M; Cortelezzi A; Laurenti L; Melpignano A; Zinzani PL; Molica S; Re F; Andriani A; Vincelli DI; Visco C; Gozzetti A; Orlandi EM; Trentin L; Tani M; Califano C; Tagariello G; Ghia P; Caputo MD; Salaroli A; Innocenti I; Frustaci A; Vitale C; Petulla M; de Fabritiis P; Vignetti M; Fazi P; Foa R
Meeting abstract: BLOOD. 2016;128(22):3235

Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients

Palma M; Krstic A; Berglof A; Wang Q; Blomberg E; Meinke S; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; Kimby E; Hoglund P; Mansson R; Osterborg A; Smith E
Meeting abstract: ANNALS OF ONCOLOGY. 2016;27:vi530

First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor

Mellstedt H; Hojjat-Farsangi M; Daneshmanesh AH; Moshfegh A; Bystrom S; Norin M; Olin T; Schultz J; Vagberg J; Osterborg A
Review: JOURNAL OF DRUG TARGETING. 2016;24(5):373-385

Ibrutinib-A double-edge sword in cancer and autoimmune disorders

Kokhaei P; Jadidi-Niaragh F; Jahromi AS; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Review: CANCER TREATMENT REVIEWS. 2016;45:68-75

New perspectives on complement mediated immunotherapy

Stasilojc G; Osterborg A; Blom AM; Okroj M
Meeting abstract: BLOOD. 2015;126(23):2912

First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells

Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Vagberg J; Styrbjorn B; Schultz J; Olsson E; Lofberg C; Norstrom C; Norin M; Olin T; Osterborg A; Mellstedt H
Meeting abstract: BLOOD. 2015;126(23):1745

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

Hansson L; Winqvist M; Asklid A; Andersson P-O; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Osterborg A
Review: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2015;82(3):208-217

Targets for Ibrutinib Beyond B Cell Malignancies

Berglof A; Hamasy A; Meinke S; Palma M; Krstic A; Mansson R; Kimby E; Osterborg A; Smith CIE
Letter: HAEMATOLOGICA. 2015;100(8):e311-e314

Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

Osterborg A; Jewell RC; Padmanabhan-Iyer S; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Furman RR; Robak T; Hillman P; Trneny M; Dyer MJS; Piotrowska M; Kozak T; Gupta IV; Phillips JL; Goldstein N; Struemper H; Losic N; Lisby S; Wierda WG
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2015;169(3):455-458

The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies

Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
Meeting abstract: BLOOD. 2014;124(21):4684

Ofatumumab (OFA) Vs. Physician's Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242

Osterborg A; Udvardy M; Zaritskey A; Andersson P-O; Grosicki S; Mazur G; Kaplan P; Steurer M; Schuh A; Montillo M; Kryachok I; Middeke JM; Kulyaba Y; Rekhtman G; Gorczyca M; Daly S; Chang C-N; Lisby S; Gupta I
Review: SEMINARS IN CANCER BIOLOGY. 2014;29:21-31

The receptor tyrosine kinase ROR1-An oncofetal antigen for targeted cancer therapy

Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2014;74(19):3184

Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease region

Moshfegh A; Hogfeldt T; Jaing C; Lundahl J; Osterborg A; Loughlin KM; Gardner SN; Gharizadeh B; Porwit A; Bahnassy AA; Zekri A-RN; Khaled HM; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2014;74(19):4770

Anti-ROR1 monoclonal antibodies induce apoptosis in pancreatic cancer cells via the PI3-kinase/AKT/mTOR pathway

Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Mikaelsson E; Khan AS; Osterborg A; Mellstedt H
Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2014;89(1):1-15

Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis-A critical review

Beguin Y; Aapro M; Ludwig H; Mizzen L; Osterborg A
Meeting abstract: MOLECULAR IMMUNOLOGY. 2013;56(3):292

Complement-dependent cytotoxicity exerted by two therapeutic anti-CD20 mAbs: Rituximab and ofatumumab in human B-cell malignant cell lines and primary cultures

Okroj M; Eriksson I; Osterborg A; Blom A
Review: CANCER TREATMENT REVIEWS. 2013;39(6):632-639

Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies

Okroj M; Osterborg A; Blom AM
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2012;159(5):608-612

Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression

Sylvan SE; Rossmann E; Mozaffari F; Porwit A; Norin S; Karlsson C; Hansson L; Lundin J; Osterborg A
Meeting abstract: BLOOD. 2012;120(21):1612

Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study

Witzens-Harig M; Ho AD; Kuhnt E; Trneny M; Rieger M; Osterborg A; Pettengell R; Stevens R; Gill DS; Walewski J; Loeffler M; Pfreundschuh M
Meeting abstract: BLOOD. 2012;120(21):4583

Dishevelled Proteins of Wnt Signaling Pathways Are Highly Expressed in Chronic Lymphocytic Leukemia

Khan AS; Sandin A; Osterborg A; Hojjat-Farsangi M; Mellstedt H; Moshfegh A
Meeting abstract: BLOOD. 2012;120(21):1769

Monoclonal Antibody Against ROR1 in Chronic Lymphocytic Leukemia Cells Induced Apoptosis Via PI3-Kinase/AKT/CREB Pathway

Daneshmanesh AH; Hojjat-Farsangi M; Sandin A; Khan AS; Moshfegh A; Jeddi-Tehrani M; Osterborg A; Mellstedt H
Review: ANNALS OF ONCOLOGY. 2012;23(8):1954-1962

Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron

Aapro M; Osterborg A; Gascon P; Ludwig H; Beguin Y
Meeting abstract: CANCER RESEARCH. 2012;72:3027

Dishevelled proteins are highly upregulated in chronic lymphocytic leukemia

Khan AS; Osterborg A; Moshfegh A; Mellstedt H
Other: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(4):587-591

First International Meeting of the Thematic Centre for Immune Modulatory Therapies for Autoimmunity and Cancer (IMTAC) 13-14 June 2011, Ljusterö, Sweden.

Choudhury A; Höglund P; Kiessling R; Kärre K; Lundqvist A; Malmberg K; Mellstedt H; Scheynius A; Winqvist O; Osterborg A
Other: MEDICAL ONCOLOGY. 2011;28(4):1626

RETRACTED ARTICLE: Survival of MM cells is dependent on Notch signaling.

Wiernik PH; Österborg A
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(17):e525-e526

Too-Low Iron Doses and Too Many Dropouts in Negative Iron Trial?

Aapro M; Beguin Y; Birgegard G; Gascon P; Hedenus M; Osterborg A
Letter: BLOOD CANCER JOURNAL. 2011;1(6):e22

Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia

Karlsson C; Dahl H; Lundin J; Rossmann E; Brytting M; Mellstedt H; Linde A; Osterborg A
Review: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2010;10(5):361-368

Ofatumumab: A New CD20 Monoclonal Antibody Therapy for B-Cell Chronic Lymphocytic Leukemia

O'Brien S; Osterborg A
Corrigendum: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2010;10(2):157

Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab (vol 9, pg E36, 2009)

Wierda W; Kipps T; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJS; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell C; Osterborg A
Meeting abstract: CLINICAL LYMPHOMA AND MYELOMA. 2009;9(6):e36

Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab

Wierda W; Kipps T; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJS; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell C; Osterborg A
Meeting abstract: BLOOD. 2009;114(22):3433-1334

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab

Osterborg A; Ronn BB; Jewell RC; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJS; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Arning M; Losic N; Davis R; Wilms J; Russell CA; Wierda WG
Review: LEUKEMIA. 2009;23(11):1980-1988

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia

Osterborg A; Foa R; Bezares RF; Dearden C; Dyer MJS; Geisler C; Lin TS; Montillo M; van Oers MHJ; Wendtner C-M; Rai KR
Published conference paper: JOURNAL OF CLINICAL ONCOLOGY. 2009;27(17):2838-2847

Pooled Analysis of Individual Patient-Level Data From All Randomized, Double-Blind, Placebo-Controlled Trials of Darbepoetin Alfa in the Treatment of Patients With Chemotherapy-Induced Anemia

Ludwig H; Crawford J; Osterborg A; Vansteenkiste J; Henry DH; Fleishman A; Bridges K; Glaspy JA
Review: CURRENT HEMATOLOGIC MALIGNANCY REPORTS. 2009;4(1):47-53

Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.

Osterborg A; Karlsson C; Lundin J
Published conference paper: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2008;57(11):1705-1710

Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia

Palma M; Adamson L; Hansson L; Kokhaei P; Rezvany R; Mellstedt H; Oesterborg A; Choudhury A
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2008;83(11):880

ESAs not the culprit: More studies required

Ludwig H; Anderson K; Dammacco F; Hedenus M; Osterborg A; Durie B
Editorial comment: LANCET ONCOLOGY. 2008;9(5):412-413

Erythropoietins should be used according to guidelines

Aapro MS; Birgegard G; Bokemeyer C; Cornes P; Foubert J; Gascon P; Glaspy J; Hellstrom-Lindberg E; Link H; Ludwig H; Osterborg A; Repetto L; Soubeyran P
Corrigendum: LEUKEMIA. 2008;22(2):462

Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies:: a randomized multicenter study (vol 21, pg 627, 2007)

Hedenus M; Birgegard G; Nasman P; Ahlberg L; Karlsson T; Lauri B; Lundin J; Larfars G; Osterborg A
Meeting abstract: BLOOD. 2007;110(11):999A

Zanolimumab (HuMax-CD4™), a fully human monoclonal antibody:: Efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4⁺ T-cell lymphoma

d'Amore F; Radford J; Jerkeman M; Relander T; Tilly H; Osterborg A; Morschhauser F; Gramatzki M; Dreyling M; Bang B; Baadsgaard O; Hagberg H
Meeting abstract: BLOOD. 2007;110(11):4674-242B

Comparison of gene expression between T cells from CLL patients, myeloma patients and healthy individuals

Choudhury A; Osterborg A; Mashavakhi K; Mosfegh A; Kiaii S; Mellsted H
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2007;5(4):147-148

Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA):: an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin alfa (DA)

Glaspy J; Osterborg A; Ludwig H; Fleishman A; Lillie T; Suto T; Crawford J
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2007;5(4):142-143

Patient-level integrated analysis of data from 6 randomized, double-blind, placebo-controlled trials of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA)

Ludwig H; Crawford J; Osterborg A; Fleishman A; Lillie T; Sueto T; Glaspy J
Review: EUROPEAN JOURNAL OF CANCER. 2007;43(3):510-519

Preclinical studies of erythropoietin receptor expression in tumour cells:: Impact on clinical use of erythropoietic proteins to correct cancer-related anaemia

Osterborg A; Aapro M; Cornes P; Haselbeck A; Hayward CRW; Jelkmann W
Review: EUROPEAN JOURNAL OF CANCER. 2007;43(2):258-270

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer:: 2006 update

Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P
Letter: LEUKEMIA. 2006;20(12):2204-2007

Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia:: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation

Karlsson C; Norin S; Kimby E; Sander B; MacDonald AP; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Meeting abstract: BLOOD. 2006;108(11):4B

Functional iron deficiency effectively overcome by adjuvant IV iron during epoetin treatment.

Birgegard G; Osterborg A; Hedenus M
Meeting abstract: BLOOD. 2006;108(11):770A

Zanolimumab, a fully human monoclonal antibody:: Preliminary results of an ongoing clinical trial in CD4⁺ peripheral T-cell lymphomas (PTCL)

d'Amore F; Relander T; Jerkeman M; Hagberg H; Osterborg A; Johnson P; Radford JA; Hancock BW; Gramatzki M; Schmitz N; Tilly H; Morschhauser F; Lisby S; Baadsgaard O
Published conference paper: ANNALS OF ONCOLOGY. 2006;17:x144-x154

The biology and treatment of chronic lymphocytic leukemia

Palma M; Kokhaei P; Lundin J; Choudhury A; Mellstedt H; Osterborg A
Review: SEMINARS IN ONCOLOGY. 2006;33(2):S29-S35

Strategies in the management of alemtuzumab-related side effects

Osterborg A; Karlsson C; Lundin J; Kimby E; Mellstedt H
Letter: BLOOD. 2005;105(10):4148-4149

No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome

Lundin J; Kennedy B; Dearden C; Dyer MJS; Österborg A
Meeting abstract: BLOOD. 2004;104(11):184A-185A

Targeting the insulin-like growth factor-i receptor (IGF-IR) in multiple myeloma cells using selective IGF-IR tyrosine kinase inhibitors.

Stromberg T; Ekman S; Girnita L; Lennartsson J; Hellman U; Carlson K; Osterborg A; Vanderkerken K; Axelson M; Larsson O; Jernberg-Wiklund H
Meeting abstract: BLOOD. 2004;104(11):689A

T-cell function in patients with B-cell chronic lymphocytic leukemia (B-CLL) following alemtuzumab (Campath®) or fludarabine treatment.

Kiaii S; Mozaffari F; Lundin J; Rezvany R; Chudhury A; Mellstedt H; Osterborg A
Meeting abstract: BLOOD. 2004;104(11):288B

Comparison of antigen-loading strategies for DC-based immunotherapy of B-CLL.

Mellstedt H; Kokhaei P; Osterborg A; Choudhury A
Meeting abstract: BLOOD. 2004;104(11):54A

Downregulating the fibromodulin gene by short interfering RNA causes B-CLL cell death.

Choudhury A; Derkow K; Mikaelsson E; Kokhaei P; Österborg A; Rabbani H; Mellstedt H
Meeting abstract: BLOOD. 2004;104(11):277A

Virus reactivation profile as assessed by PCR and serology pattern following first-line alemtuzumab (anti-CD52 monoclonal antibody, Campath®) therapy in patients with B-CLL.

Karlsson C; Dahl H; Linde A; Lundin J; Björkholm M; Mellstedt H; Osterborg A
Meeting abstract: BLOOD. 2004;104(11):419A

Long-term Id vaccination combined with IL-12 or IL-12 and GM-CSF in early stage multiple myeloma patients

Hansson L; Abdalla AO; Rabbani H; Osterborg A; Mellstedt H
Review: CURRENT TREATMENT OPTIONS IN ONCOLOGY. 2004;5(3):203-214

Therapy for mycosis fungoides.

Lundin J; Osterborg A
Published conference paper: SEMINARS IN ONCOLOGY. 2004;31(3):12-18

New erythropoietic proteins: Rationale and clinical data

Osterborg A
Review: CLINICAL ADVANCES IN HEMATOLOGY AND ONCOLOGY. 2004;2(4):233-241

Anemia in multiple myeloma.

Ludwig H; Pohl G; Osterborg A
Review: CLINICAL LYMPHOMA AND MYELOMA. 2004;4(4):220-227

Management guidelines for use of alemtuzumab in B-Cell chronic lymphocytic leukemia

Keating M; Coutré S; Rai K; Österborg A; Faderl S; Kennedy B; Kipps T; Bodey G; Byrd JC; Rosen S; Dearden C; Dyer MJS; Hillmen P
Letter: LEUKEMIA. 2003;17(11):2252-2254

T-cell signaling and costimulatory molecules in B-chronic lymphocytic leukemia (B-CLL):: an increased abnormal expression by advancing stage

Rossmann ED; Jeddi-Tehrani M; Österborg A; Mellstedt H
Letter: CANCER. 2003;97(12):3125-3126

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy

Österborg A; Brandberg Y
Editorial comment: DRUGS. 2003;63(12):1245-1246

Alemtuzumab -: A viewpoint by Anders!Osterborg

Österborg A
Review: HEMATOLOGY JOURNAL. 2002;3(3):121-130

Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations.

Ludwig H; Rai K; Blade J; Dammacco F; Degos L; Itri L; Kyle R; Liso V; Littlewood TJ; Mandelli F; Meloni G; Molica S; Osterborg A; Pangalis GA; San Miguel J; Schmitt B; Voliotis D
Review: MEDICAL ONCOLOGY. 2000;17:S17-S22

The role of recombinant human erythropoietin in the management of anaemic cancer patients:: focus on haematological malignancies

Österborg A
Published conference paper: ACTA ONCOLOGICA. 2000;39(7):797-800

Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma

Österborg A; Henriksson L; Mellstedt H
Review: CURRENT OPINION IN HEMATOLOGY. 1999;6(3):169-175

Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors.

Mellstedt H; Fagerberg J; Frödin JE; Henriksson L; Hjelm-Skoog AL; Liljefors M; Ragnhammar P; Shetye J; Osterborg A
Editorial comment: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1999;16(1):1

Untitled

Österborg A; Wiernik PH
Review: SEMINARS IN IMMUNOPATHOLOGY. 1999;21(1):19-35

T cell receptor usage in malignant diseases

Halapi E; Jeddi-Tehrani M; Österborg A; Mellstedt H
Review: MEDICAL ONCOLOGY. 1998;15 Suppl 1:S47-S49

Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned?

Osterborg A
Review: LAKARTIDNINGEN. 1998;95(13):1405-1410

[Vaccination against cancer soon a therapeutic possibility. B-cell tumors, colonic cancer and melanoma may be suitable for this treatment].

Mellstedt H; Fagerberg J; Osterborg A
Editorial comment: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1996;13(3):R3

New applications of GM-CSF

Osterborg A
Visa fler

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI